Dr Reddy's Laboratories Ltd
DRREDDYDr Reddy's Laboratories Ltd
DRREDDY
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 20.46 | 4.04 | 0.58% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.01 | 6.09 | 0.55% |
Forecast & Ratings
Detailed Forecast from 27 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Zydus Lifesciences Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15,863.30 | 14,367.60 | 14,436.20 | 15,829.50 | 18,193.70 | 19,386.90 | 22,099.90 | 25,762.20 | 28,920.10 | 28,928.50 | ||||||||||
Raw Materials | 3,854.20 | 3,819.80 | 4,081.00 | 4,770.20 | 5,530.70 | 6,869.40 | 7,796.10 | 7,586.80 | 8,889.20 | 20,086.40 | ||||||||||
| Power & Fuel Cost | 315.20 | 330.10 | 329.30 | 329.10 | 314.80 | 320.50 | 390.50 | 477.40 | 533.90 | |||||||||||
| Employee Cost | 3,117.40 | 3,106.80 | 3,214.90 | 3,356.20 | 3,380.20 | 3,629.90 | 3,885.80 | 4,646.60 | 5,030.10 | |||||||||||
| Selling & Administrative Expenses | 3,007.00 | 3,287.10 | 2,106.10 | 2,235.30 | 2,184.20 | 2,398.30 | 2,976.10 | 3,199.30 | 3,710.20 | |||||||||||
| Operating & Other expenses | 1,689.20 | 1,180.10 | 2,198.50 | 1,579.20 | 3,636.70 | 1,959.50 | 2,729.00 | 2,410.60 | 1,914.60 | |||||||||||
EBITDA | 3,880.30 | 2,643.70 | 2,506.40 | 3,559.50 | 3,147.10 | 4,209.30 | 4,322.40 | 7,441.50 | 8,842.10 | 8,842.10 | ||||||||||
| Depreciation/Amortization | 938.90 | 1,026.60 | 1,077.20 | 1,134.80 | 1,163.10 | 1,228.80 | 1,165.20 | 1,250.20 | 1,470.00 | 1,470.00 | ||||||||||
| PBIT | 2,941.40 | 1,617.10 | 1,429.20 | 2,424.70 | 1,984.00 | 2,980.50 | 3,157.20 | 6,191.30 | 7,372.10 | 7,372.10 | ||||||||||
| Interest & Other Items | 82.60 | 63.40 | 78.80 | 88.90 | 98.30 | 97.00 | 95.80 | 142.80 | 171.10 | 171.10 | ||||||||||
| PBT | 2,858.80 | 1,553.70 | 1,350.40 | 2,335.80 | 1,885.70 | 2,883.50 | 3,061.40 | 6,048.50 | 7,201.00 | 7,201.00 | ||||||||||
| Taxes & Other Items | 728.20 | 261.60 | 403.60 | 385.80 | -140.30 | 931.90 | 878.90 | 1,541.20 | 1,623.10 | 1,623.10 | ||||||||||
| Net Income | 2,130.60 | 1,292.10 | 946.80 | 1,950.00 | 2,026.00 | 1,951.60 | 2,182.50 | 4,507.30 | 5,577.90 | 5,577.90 | ||||||||||
| EPS | 124.97 | 76.83 | 57.10 | 117.48 | 121.96 | 117.40 | 131.19 | 270.75 | 334.66 | 334.37 | ||||||||||
| DPS | 20.00 | 20.00 | 20.00 | 20.00 | 25.00 | 25.00 | 30.00 | 40.00 | 40.00 | 40.00 | ||||||||||
| Payout ratio | 0.16 | 0.26 | 0.35 | 0.17 | 0.20 | 0.21 | 0.23 | 0.15 | 0.12 | 0.12 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Dr Reddy's Laboratories Ltd | 20.46 | 4.04 | 0.58% |
| Sun Pharmaceutical Industries Ltd | 41.74 | 5.96 | 0.81% |
| Zydus Lifesciences Ltd | 31.44 | 5.49 | 0.25% |
| Cipla Ltd | 29.39 | 5.11 | 0.87% |
Price Comparison
Compare DRREDDY with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Decreased Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has decreased by 2.22%
Shareholding Pattern
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 2.10%
Top 5 Mutual Funds holding Dr Reddy's Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
ICICI Prudential Innovation Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0641% | Percentage of the fund’s portfolio invested in the stock 1.41% | Change in the portfolio weight of the stock over the last 3 months -0.06% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 33/93 (-3) |
Quant Large Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0617% | Percentage of the fund’s portfolio invested in the stock 4.65% | Change in the portfolio weight of the stock over the last 3 months 4.65% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/44 (+10) |
HDFC Pharma and Healthcare Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0385% | Percentage of the fund’s portfolio invested in the stock 5.30% | Change in the portfolio weight of the stock over the last 3 months 5.30% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 4/39 (+27) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Dr Reddy's Laboratories Ltd
Events
Dividend Trend
No Dividend Cuts
DRREDDY has increased or maintained dividend levels over the last 5 years
Dividend Yield
Current dividend yield is 0.58%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹5.85 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 16, 2024
Dividend/Share
₹40.00
Ex DateEx Date
Jul 16, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹40.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 11, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Jul 11, 2022
Cash Dividend
Ex DateEx DateJul 9, 2021
Dividend/Share
₹25.00
Ex DateEx Date
Jul 9, 2021
Cash Dividend
Ex DateEx DateJul 13, 2020
Dividend/Share
₹25.00
Ex DateEx Date
Jul 13, 2020
Dr Reddy’s Labs Q1 Preview: Market share loss in products to drag profits
Nestle India And Dr Reddy’s Laboratories Form Joint Venture Company
Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy's will market Vonoprazan tablets under its own trademark VONO and it would be available in two strengths, 10mg and 20mg. Acid peptic disorders (APD), which include gastroesophageal reflux disease (GERD) and peptic ulcer disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms. M.V. Ramana, CEO ' Branded Markets (India & Emerging Markets), Dr. Reddy's, said: 'For over three decades, patients and healthcare professionals have trusted our products in the gastrointestinal segment including well-known brands such as Omez, Razo and others. Leveraging our expertise in this therapy area, we are pleased to make the first-in-class drug Vonoprazan (Vono) available to patients in India. The non-exclusive patent licensing agreement with Takeda is part of our continuous efforts to make innovative medicines available to patients in India through strategic collaborations to meet unmet needs and enhance standard of care. Dr Reddy's Labs is engaged in providing medicines. The firm operates in three segments: global generics, pharmaceutical services and active ingredients (PSAI) and proprietary products. The drug maker reported 36.25% increase in net profit to Rs 1,307 crore on 12.48% rise in revenue from operations to Rs 7,083 crore in Q4 FY24 over Q4 FY23. The scrip shed 0.04% to currently trade at Rs 6662.50 on the BSE. Powered by Capital Market - Live
Dr. Reddy's Laboratories announced that it has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company (Takeda) to commercialise Vonoprazan tablets in India. Vonoprazan is a novel, orally active potassium competitive acid blocker (PCAB), used to treat reflux esophagitis and other acid peptic disorders. Dr. Reddy's will market Vonoprazan tablets under its own trademark VONO' to be available in two strengths, 10mg and 20mg. Acid Peptic Disorders (APD), which include Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), are very common in India. A pan-Indian cross-sectional survey of clinicians showed APD prevalence to be in the range of 37-39%. It is more common in the 18-59 age group, with heart burn and epigastric pain as common symptoms. Powered by Capital Market - Live
Dr Reddy’s inks licensing pact with Takeda to sell gastrointestinal drug
Dr Reddy’s signs non-exclusive patent licensing agreement with Takeda to commercialise gastrointestinal drug in India
Dr Reddy’s, Sun Pharma recall drugs in US due to production issues: USFDA
Dr Reddy’s, Sun Pharma recall drugs in US market: USFDA
Dr Reddy’s Lab jumps after arm inks pact to acquire Nicotinell brand
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 12.81%, vs industry avg of 8.96%
Increasing Market Share
Over the last 5 years, market share increased from 6.99% to 7.86%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 23.39%, vs industry avg of 15.15%